Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25224414 | 0.83 | PLAU (0.43) | PLAULMNACYP2C9TSHRAPEX1 | |
| SCHEMBL30481308 | 0.83 | PLAU (0.43) | PLAULMNACYP2C9TSHRAPEX1 | |
| SCHEMBL18378745 | 0.81 | PLAU (0.42) | PLAULMNA | |
| SCHEMBL22493741 | 0.81 | PLAU (0.46) | PLAULMNA | |
| SCHEMBL19534297 | 0.81 | PLAU (0.46) | PLAU | |
| Hydrochloric Acid SCHEMBL20399974 | 0.79 | PLAU (0.44) | PLAU | |
| SCHEMBL31091988 | 0.78 | PLAU (0.43) | PLAULMNA | |
| SCHEMBL23706067 | 0.78 | PLAU (0.43) | PLAULMNA | |
| SCHEMBL18379081 | 0.78 | PLAU (0.40) | PLAU | |
| SCHEMBL7995407 | 0.77 | LMNA (0.41) | PLAULMNACYP2C9TSHRAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541792-B1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10736883-B2 | Triazole furan compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3541792-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190275008-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018097944-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275008-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, APLNR | PLAU 2262/4885LMNA 3247/4885CYP2C9 643/4885 |
| US-10736883-B2 | Triazole furan compounds as agonists of the APJ receptor | TBXA2R, AGTR1, APLNR | PLAU 2262/4885LMNA 3247/4885CYP2C9 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.